EquiTrex®350 10ml vial
Boldenone Undecylenate 350mg/mll, 10 mL Multidose Vial
Each 1 ml of CYPIOTREX350 contains
350 mg Boldenone Undecylenate
Ethlyl Oleate q.s.
For Intramuscular Administration
Indication & Dosage:
FOR INTRAMUSCULAR USE IN HORSES ONLY
Certain pathophysiological or catabolic processes in animals.
As anabolic after debilitating illness
The dosage for horses is 0.28 to 1.10 mg/kg (0.13-0.5 mg/lb) of body
weight intramuscularly. Treatment may be repeated every 2 to 3 weeks.
The condition should be assessed by a veterinarian to determine the
duration of treatment; however, most horses will respond with one or
In the absence of data on the effect of boldenone undecylenate on immature colts and
fillies, stallions, pregnant mares or brood mares during the breeding season, this drug
should not be used in these animals.
For horses only. This drug is not to be administered to horses that are to be slaughtered
for use in food. Keep out of reach of children.
Adverse Drug Reactions
Treatment with EQUITREX injectable (boldenone undecylenate injection) may
result in androgenic effects (masculinization, behavioural effects) being expressed
in some animals. If these effects occur, they may persist for up to 6 to 8 weeks.
No additional injections of boldenone undecylenate should be administered.
May increase effects of oral anticoagulants, insulin,
oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).
Category X: Studies in animals beings have demonstrated foetal
abnormalities or there is evidence of foetal risk.
Store at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in a tightly-closed container. Store away from heat, moisture, and light.
Do not store in the bathroom. Keep out of the reach of children and away from pets.
Concentrex Laboratiories N. V., Moerstraat 58, 9031, Gent, Belgium
Reg. No. Licence: 253/55-C9/2010/BE
Manufactured under WHO cGMP guidelines
Date of Preparation : 19 july 2010